FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135427853> ?p ?o ?g. }

• W2135427853 endingPage "8" @default.
• W2135427853 startingPage "3331" @default.
• W2135427853 abstract "The oncogenic protein Bcl-2 functions as a potent inhibitor of programmed cell death. This survival activity has been shown in some settings to be influenced by the Bcl-2 phosphorylation state. It has been demonstrated that treatment with microtubule-targeted agents results in phosphorylation of both Raf-1 kinase and Bcl-2. The Bcl-2-related family member Bcl-xL also exhibits a death suppressive activity, but its potential for phosphorylation following exposure to drugs that interact with microtubules has not been evaluated. Several tumor cell lines with low or undetectable levels of Bcl-2 protein expression were found to express Bcl-xL. A more slowly migrating Bcl-xL band was observed on immunoblots after cells were treated with microtubule-targeted agents. The appearance of this band was responsive to dose and was absent when the cell lysates were treated with lambda protein phosphatase. Using a Bcl-xL-specific monoclonal antibody, the phosphorylated form of Bcl-xL was immunoprecipitated from cells treated with paclitaxel and metabolically labeled with 32P-labeled inorganic orthophosphate. Herein, we report that Bcl-xL is phosphorylated in malignant cells after incubation with agents that target tubulin, including paclitaxel, vincristine, vinblastine, colchicine, and nocodazole. Moreover, paclitaxel-resistant ovarian carcinoma cell lines that have mutations in tubulin failed to exhibit phosphorylation of Bcl-xL after paclitaxel exposure, but they did demonstrate Bcl-xL phosphorylation in the presence of other tubulin-targeting agents. As observed for Bcl-2, phosphorylation of Bcl-xL was accompanied by phosphorylation of Raf-1. Interestingly, phosphorylation of these three proteins failed to occur or was much less pronounced when cells grown at high density were challenged with drug. Also, reduced Raf-1 expression, observed after treatment of cells with geldanamycin prior to and during incubation with the microtubule-active drugs, correlated with diminished Bcl-xL phosphorylation. Taken together, these results suggest that Bcl-xL, like Bcl-2, is phosphorylated by agents that disrupt microtubule architecture. By analogy with Bcl-2, this phosphorylation may play a critical role in modulating Bcl-xL function and may be an important determinant of microtubule-directed chemotherapeutic efficacy in human tumors." @default.
• W2135427853 created "2016-06-24" @default.
• W2135427853 creator A5006092876 @default.
• W2135427853 creator A5020463639 @default.
• W2135427853 creator A5045764409 @default.
• W2135427853 creator A5049524331 @default.
• W2135427853 creator A5050912375 @default.
• W2135427853 date "1998-08-01" @default.
• W2135427853 modified "2023-10-16" @default.
• W2135427853 title "Bcl-xL is phosphorylated in malignant cells following microtubule disruption." @default.
• W2135427853 cites W1502312403 @default.
• W2135427853 cites W1547132539 @default.
• W2135427853 cites W1568104635 @default.
• W2135427853 cites W1570441204 @default.
• W2135427853 cites W1599115647 @default.
• W2135427853 cites W1611278546 @default.
• W2135427853 cites W161930446 @default.
• W2135427853 cites W1621124914 @default.
• W2135427853 cites W1752310561 @default.
• W2135427853 cites W1909273809 @default.
• W2135427853 cites W1911989431 @default.
• W2135427853 cites W1966539065 @default.
• W2135427853 cites W1968965382 @default.
• W2135427853 cites W1970834072 @default.
• W2135427853 cites W1979995768 @default.
• W2135427853 cites W1998595310 @default.
• W2135427853 cites W2016223901 @default.
• W2135427853 cites W2027039228 @default.
• W2135427853 cites W2032221839 @default.
• W2135427853 cites W2033873142 @default.
• W2135427853 cites W2039355845 @default.
• W2135427853 cites W2052452850 @default.
• W2135427853 cites W2061354386 @default.
• W2135427853 cites W2070862399 @default.
• W2135427853 cites W2071468325 @default.
• W2135427853 cites W2093628776 @default.
• W2135427853 cites W2118873545 @default.
• W2135427853 cites W2130866079 @default.
• W2135427853 cites W2139306838 @default.
• W2135427853 cites W2143051140 @default.
• W2135427853 cites W2158552404 @default.
• W2135427853 cites W2161641464 @default.
• W2135427853 cites W2265226651 @default.
• W2135427853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9699663" @default.
• W2135427853 hasPublicationYear "1998" @default.
• W2135427853 type Work @default.
• W2135427853 sameAs 2135427853 @default.
• W2135427853 citedByCount "42" @default.
• W2135427853 countsByYear W21354278532012 @default.
• W2135427853 countsByYear W21354278532013 @default.
• W2135427853 countsByYear W21354278532015 @default.
• W2135427853 countsByYear W21354278532016 @default.
• W2135427853 countsByYear W21354278532018 @default.
• W2135427853 countsByYear W21354278532019 @default.
• W2135427853 countsByYear W21354278532022 @default.
• W2135427853 crossrefType "journal-article" @default.
• W2135427853 hasAuthorship W2135427853A5006092876 @default.
• W2135427853 hasAuthorship W2135427853A5020463639 @default.
• W2135427853 hasAuthorship W2135427853A5045764409 @default.
• W2135427853 hasAuthorship W2135427853A5049524331 @default.
• W2135427853 hasAuthorship W2135427853A5050912375 @default.
• W2135427853 hasConcept C11960822 @default.
• W2135427853 hasConcept C121608353 @default.
• W2135427853 hasConcept C142669718 @default.
• W2135427853 hasConcept C1491633281 @default.
• W2135427853 hasConcept C153911025 @default.
• W2135427853 hasConcept C190283241 @default.
• W2135427853 hasConcept C20418707 @default.
• W2135427853 hasConcept C2776789625 @default.
• W2135427853 hasConcept C2777292972 @default.
• W2135427853 hasConcept C2778198054 @default.
• W2135427853 hasConcept C2779363559 @default.
• W2135427853 hasConcept C31573885 @default.
• W2135427853 hasConcept C502942594 @default.
• W2135427853 hasConcept C54355233 @default.
• W2135427853 hasConcept C55493867 @default.
• W2135427853 hasConcept C81885089 @default.
• W2135427853 hasConcept C84425145 @default.
• W2135427853 hasConcept C86803240 @default.
• W2135427853 hasConcept C87325107 @default.
• W2135427853 hasConcept C95444343 @default.
• W2135427853 hasConcept C97029542 @default.
• W2135427853 hasConceptScore W2135427853C11960822 @default.
• W2135427853 hasConceptScore W2135427853C121608353 @default.
• W2135427853 hasConceptScore W2135427853C142669718 @default.
• W2135427853 hasConceptScore W2135427853C1491633281 @default.
• W2135427853 hasConceptScore W2135427853C153911025 @default.
• W2135427853 hasConceptScore W2135427853C190283241 @default.
• W2135427853 hasConceptScore W2135427853C20418707 @default.
• W2135427853 hasConceptScore W2135427853C2776789625 @default.
• W2135427853 hasConceptScore W2135427853C2777292972 @default.
• W2135427853 hasConceptScore W2135427853C2778198054 @default.
• W2135427853 hasConceptScore W2135427853C2779363559 @default.
• W2135427853 hasConceptScore W2135427853C31573885 @default.
• W2135427853 hasConceptScore W2135427853C502942594 @default.
• W2135427853 hasConceptScore W2135427853C54355233 @default.
• W2135427853 hasConceptScore W2135427853C55493867 @default.
• W2135427853 hasConceptScore W2135427853C81885089 @default.

• next